In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...
Read More
In a nutshell This study evaluated the effectiveness and safety of a venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Decadron combination with or without bortezomib (Velcade) in patients with relapsed or refractory (RR) multiple myeloma (MM). The authors concluded that these treatment combinations produced high...
Read More
In a nutshell This study assessed the safety and impact on the growth of nilotinib (Tasigna) in children with chronic myeloid leukemia (CML). The data indicated reduced growth rates with nilotinib treatment in children with CML. Some background Chronic myeloid leukemia (CML) is rare in children. However, it affects younger patients more...
Read More
In a nutshell This study investigated the effects of adding chemotherapy to trastuzumab (Herceptin) treatment on cognitive (thinking and reasoning) functioning in older patients with HER2-positive (HER2+) breast cancer (BC). The data showed that the addition of chemotherapy did not impact cognitive functioning in these women. Some...
Read More
In a nutshell This study aimed to compare the effects of oral hyaluronic acid (HA) and injections of HA into the scar tissues plaque, against the effects of injections alone in Peyronie's disease (PD). The results suggest that the combination treatment was more effective than injections alone. Some background PD is a noncancerous condition...
Read More
In a nutshell This study aimed to investigate depression and cognitive (thinking and reasoning) functions after taxane-based chemotherapy in patients with breast cancer. This study concluded taxane-based chemotherapy commonly leads to cognitive impairment in these patients, but some functions improve or remain stable after stopping...
Read More
In a nutshell This study aimed to investigate the effects of adherence to hormonal therapy (HT) and radiation on the outcomes of older patients with early-stage breast cancer (BC). This study concluded that the lack of adherence to HT and omitting radiation can lead to poorer outcomes for these...
Read More
In a nutshell This study aimed to examine the effectiveness and safety of cemiplimab (Libtayo) in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC) with a high quantity of PD-L1 protein. The study concluded cemiplimab improved survival of these patients compared to standard chemotherapy. Some background NSCLC...
Read More
In a nutshell This article reviewed the common side effects of estrogen deprivation during hormonal therapy for women with breast cancer and provided an update on alternative therapies to manage these symptoms. Some background Breast cancer (BC) is one of the most common cancers affecting women worldwide. Some BC cells grow in response to female...
Read More
In a nutshell This study looked at the effectiveness of durvalumab (Imfinzi) with or without tremelimumab plus platinum-etoposide (Etopophos) (PE) versus PE-alone for the treatment of extensive-stage small-cell lung cancer (ESCLC). The authors found that durvalumab plus PE showed sustain survival improvement in these patients. Some background...
Read More
In a nutshell This trial was carried out to look at the effectiveness of nivolumab (Opdivo) and nivolumab plus ipilimumab (Yervoy) as neoadjuvant therapy (NAT; treatment before surgery) in treating operable non-small cell lung cancer (NSCLC). The authors found that ipilimumab and nivolumab treatment before surgery provides better...
Read More
In a nutshell This article looked at the safety and effectiveness of abemaciclib (Verzenios) plus hormonal therapy (HT) in older patients with hormone receptor-positive (HR+)/HER-2 negative (HER2-) advanced breast cancer (BC). The authors concluded that abemaciclib + HT was effective across all age groups and while higher rates of side effects...
Read More
